(Reuters) -AbbVie on Thursday lowered its forecast for 2024 adjusted profit, citing the impact of $82 million in milestones, and research and development expenses related to acquisitions. The drugmaker expects annual adjusted profit per share in the range of $10.67 to $10.87, compared with its previous forecast of $10.71 to $10.91 per share, a regulatory […]
Health
AbbVie cuts 2024 profit forecast citing R&D expenses
Audio By Carbonatix
(Reuters) -AbbVie on Thursday lowered its forecast for 2024 adjusted profit, citing the impact of $82 million in milestones, and research and development expenses related to acquisitions.
The drugmaker expects annual adjusted profit per share in the range of $10.67 to $10.87, compared with its previous forecast of $10.71 to $10.91 per share, a regulatory filing showed.
Analysts were expecting $10.88 per share, according to estimates compiled by LSEG.
AbbVie also cut its forecast for third-quarter adjusted profit per share to $2.88 to $2.92 from $2.92 to $2.96 previously.
The company said it incurred $82 million in expenses during the quarter related to collaborations, licensing agreements and other asset acquisitions.
AbbVie is scheduled to report third-quarter results on Oct. 30.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)